Alaunos Therapeutics, Inc. — 2019 Q3 Form 10-Q summary
Issuer identification: The filing is for ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP), for the quarter ended September 30, 2019, not for a registrant named Alaunos Therapeutics, Inc. The information below summarizes the filing as submitted.
Business context and reporting period
ZIOPHARM was a clinical-stage biopharmaceutical company developing cancer immunotherapies, including its Sleeping Beauty cell-engineering platform and Controlled IL-12 program. It had no recurring operating revenue and had incurred losses since inception. The financial statements are unaudited; the comparisons below are with the three and nine months ended September 30, 2018, or with December 31, 2018 for balance-sheet items.
Financial performance and liquidity
| Metric | Q3 2019 / September 30, 2019 | Comparable period / prior year-end |
|---|---|---|
| Collaboration revenue | $0 for the quarter; $0 for the nine months in the statements of operations | $0 for Q3 2018; $146,000 for nine months 2018 |
| Research and development expense | $8.641 million for Q3; $28.115 million for nine months | $8.263 million and $25.935 million, respectively, in 2018 |
| General and administrative expense | $4.807 million for Q3; $13.707 million for nine months | $4.307 million and $15.355 million, respectively, in 2018 |
| Net loss | $73.996 million for Q3; $102.050 million for nine months | $12.585 million and $40.636 million, respectively, in 2018 |
| Net loss per share, basic and diluted | $0.43 for Q3; $0.62 for nine months | $0.13 and $0.41, respectively, in 2018 |
| Cash and cash equivalents | $88.419 million | $61.729 million at December 31, 2018 |
| Working capital | $104.4 million | $74.8 million at December 31, 2018 |
| Total liabilities | $11.823 million | $9.487 million at December 31, 2018 |
| Operating cash flow | $(29.246) million for nine months | $(37.638) million for nine months 2018 |
No conventional operating margin is presented; the company was loss-making and reported no meaningful revenue base. The balance sheet includes lease liabilities, accrued expenses and accounts payable; the filing does not report borrowings or other conventional debt.
Material changes versus the prior comparable period
- Nine-month net loss increased by $61.414 million, principally because of a $60.751 million non-cash inducement-warrant expense. The charge related to replacement warrants issued to investors who exercised existing warrants early; it did not represent a comparable cash outflow.
- Nine-month R&D expense rose $2.180 million (about 8%), reflecting NCI license-related costs and increased manufacturing, development and clinical-trial spending, partly offset by lower costs for the CD33 CAR-T program transferred to Precigen.
- Nine-month G&A expense fell $1.648 million (about 11%), mainly because 2018 included higher stock-option modification and consulting costs.
- Cash increased by $26.690 million in the first nine months of 2019, versus a $39.218 million decrease in the comparable 2018 period. Financing provided $56.120 million, primarily from $52.5 million net proceeds from warrant exercises and $3.0 million from at-the-market share sales.
- Common shares outstanding rose from 161.1 million at December 31, 2018 to 181.0 million at September 30, 2019. The warrant transactions and at-the-market issuance contributed to this increase.
Outlook, management commentary, risks and unusual items
- Management estimated that the $88.4 million cash balance would fund planned operations into the first half of 2021. It had no committed sources of additional capital and said further financing would be needed for longer-term clinical development. Funding may require equity issuance, collaboration, debt or other sources; there is no assurance it will be available on acceptable terms.
- Management warned that higher-than-expected development costs, slower trial progress, or changes in program priorities could shorten the cash runway and force the company to delay, reduce or discontinue programs.
- Clinical updates included commencement of NCI’s phase 2 Sleeping Beauty TCR trial preparations, enrollment activity in the phase 2 Controlled IL-12 plus Libtayo trial, and additional enrollment in the phase 1 Controlled IL-12 plus Opdivo study. These were development updates, not evidence of approved products or established revenue.
- After quarter-end, the company entered a new MD Anderson research agreement for its TCR program. It agreed to reimburse up to $20 million in development costs beginning in 2021, pay potential milestone amounts totaling $36.5 million and low-single-digit royalties, and issued MD Anderson a warrant for 3,333,333 shares at an initial $0.001 exercise price, vesting upon clinical milestones. These obligations and the warrant are subsequent events, not September 30 balance-sheet amounts.
- Other commitments included $5.625 million remaining under the NCI CRADA and payments and potential milestones under license agreements. The filing also describes substantial clinical, regulatory, manufacturing, intellectual-property, competition and financing risks. No material legal proceeding was identified as of September 30, 2019.
- The filing contains a revenue presentation discrepancy: the statements of operations report no 2019 collaboration revenue, while MD&A says approximately $0.1 million of previously deferred revenue was recognized under ASC 605. The filing text does not provide a clear reconciliation.
Most important facts for investors to verify
- Confirm the issuer and security: this is ZIOPHARM Oncology, Inc.’s 2019 Q3 filing, with ticker ZIOP.
- Reconcile the $0 revenue in the financial statements with the MD&A reference to approximately $0.1 million recognized under ASC 605.
- Assess the cash-runway estimate against the operating cash burn, planned trial and manufacturing spending, and the absence of committed future financing.
- Review potential dilution from the 17.8 million replacement warrants issued in 2019, the at-the-market facility of up to $100 million, and the post-quarter MD Anderson warrant for 3.33 million shares.
- Evaluate the $60.751 million non-cash warrant charge separately from recurring operating costs, while considering the warrants’ potential dilution.